Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Frequently asked questions
What sector does Xeris Pharmaceuticals Inc (XERS) operate in?
Xeris Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Xeris Pharmaceuticals Inc (XERS) current stock price?
As of the latest data, Xeris Pharmaceuticals Inc stock price is $10.21, with a previous close of $10.20. Xeris Pharmaceuticals Inc gained $0.01 in the last trading session, representing a 0.1% increase.
What is Xeris Pharmaceuticals Inc (XERS) current market capitalization?
Xeris Pharmaceuticals Inc market cap is approximately 1.86 billion.
What is Xeris Pharmaceuticals Inc (XERS) Earnings Per Share (EPS)?
The trailing EPS is -$0.10, and the forward EPS is $0.37.
What is Xeris Pharmaceuticals Inc (XERS) EBITDA?
Xeris Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -20.94 million.
Does Xeris Pharmaceuticals Inc (XERS) pay dividends?
No. Xeris Pharmaceuticals Inc does not pay a dividend.
How did Xeris Pharmaceuticals Inc (XERS) perform in its most recent earnings report?
In the last report (June 30, 2026), Xeris Pharmaceuticals Inc posted an EPS surprise of -150% and a revenue surprise of 2.19%.
When is Xeris Pharmaceuticals Inc (XERS) next earnings report?
Xeris Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Xeris Pharmaceuticals Inc (XERS) beta (volatility) score?
Xeris Pharmaceuticals Inc has a beta of 0.838, meaning its volatility is roughly in line with the market.
